このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MedAdvisor マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Rick Ratliff

最高経営責任者

AU$2.0m

報酬総額

CEO給与比率	33.4%
CEO在任期間	1.9yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.7yrs
取締役会の平均在任期間	2.6yrs

経営陣の近況

Recent updates

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22

CEO報酬分析

MedAdvisor の収益と比較して、Rick Ratliff の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	n/a	n/a	-AU$9m
Sep 30 2023	n/a	n/a	-AU$10m
Jun 30 2023	AU$2m	AU$678k	-AU$11m

報酬と市場: Rickの総報酬 ($USD 1.35M ) は、 Australian市場 ($USD 649.21K ) の同規模の企業の平均を上回っています。

報酬と収益: Rickの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Rick Ratliff

1.9yrs

在職期間

AU$2,030,589

報酬

Mr. Richard Ratliff, also known as Rick, MBA IT, BChE serves as Chief Executive Officer & Managing Director and Director at MedAdvisor Limited since July 15, 2022. He serves as Chief Commercial Officer at...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Ratliff	CEO, MD & Director	1.9yrs	AU$2.03m	データなし
Ancila Desai	CFO & Joint Company Secretary	1.7yrs	AU$461.20k	データなし
Craig Schnuriger	Acting Chief Technology Officer	4.3yrs	データなし	データなし
James Rotsart	Executive VP of US & Client Relations	no data	データなし	データなし
Wayne Marinoff	President of ANZ	1.4yrs	データなし	データなし
Anshu Raghuvanshi	Joint Company Secretary	1.3yrs	データなし	データなし

1.7yrs

平均在職期間

経験豊富な経営陣: MDRの経営陣は経験豊富とはみなされません ( 1.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Ratliff	CEO, MD & Director	1.9yrs	AU$2.03m	データなし
Linda Jenkinson	Independent Non-Executive Chairman	2.3yrs	AU$373.08k	データなし
Kevin Hutchinson	Independent Non-Executive Director	1.6yrs	AU$102.62k	0.11% A$ 293.8k
Lucas Merrow	Independent Non-Executive Director	2.8yrs	AU$94.10k	0.17% A$ 470.1k
Sandra Hook	Independent Non-Executive Director	8.4yrs	AU$130.78k	0.056% A$ 154.8k
Arthur Charlaftis	Member of Advisory Board	8.3yrs	データなし	データなし
Jim Xenos	Non-Executive Director	8.6yrs	AU$84.58k	1.25% A$ 3.4m
Mike Da Gama	Member of Advisory Board	8.3yrs	AU$25.89k	データなし
Nick England	Member of Advisory Board	8.3yrs	データなし	データなし
Catherine Hill	Independent Non-Executive Director	1.1yrs	AU$5.78k	データなし
Anthony Tassone	Non-Executive Director	1.9yrs	データなし	データなし
Brett Magun	Non-Executive Director	1.1yrs	データなし	データなし

2.6yrs

平均在職期間

経験豊富なボード: MDRの取締役会は経験豊富ではない ( 2.6年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

MedAdvisor マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited Announces Board Changes

Recent updates

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven

Less than half of directors are independent

MedAdvisor Limited Announces Retirement of Robert Read as CEO

Consensus forecasts updated

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited to Report First Half, 2022 Results on Feb 25, 2022

MedAdvisor Limited Appoints Raeann Grossman to the Board as A Non-Executive Director

Independent Non-Executive Director Peter Bennetto has left the company

Non-Executive Director recently sold AU$2.5m worth of stock

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Less than half of directors are independent

Full year 2021 earnings released

Non-Executive Director has left the company

MedAdvisor Limited announced that it has received AUD 5.25 million in funding

New 90-day low: AU$0.34

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

First half 2021 earnings released: AU$0.029 loss per share (vs AU$0.024 loss in 1H 2020)

MedAdvisor Limited to Report First Half, 2021 Results on Feb 25, 2021

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

New 90-day low: AU$0.34

Non-Executive Chairman of the Board recently bought AU$70k worth of stock

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

MedAdvisor Limited Signs an Additional One-Year Deal with A Major Global Pharmaceutical Company

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

New 90-day low: AU$0.36

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

New 90-day low: AU$0.39

MedAdvisor Limited Extends Health Programs in the US

New 90-day low: AU$0.41

MedAdvisor Limited Launches ePrescribing across Australia

New 90-day low - AU$0.44

Full year earnings released

New 90-day low - AU$0.45

マネジメント基準チェック /04